Diabetic Foot Ulcers Clinical Trial
Official title:
Monochromatic Phototherapy on Diabetic Foot Ulcers. A Twenty Weeks Prospective, Randomised, Double Blind, Multi-centre, Placebo Controlled Study
The purpose of this study is to evaluate the efficacy and safety of monochromatic
phototherapy (Biolight®) on foot ulcers in diabetic patients, in comparison of placebo
phototherapy as a complementary to standard diabetic foot ulcer therapy.
The study initiated with a four week long Run In Period to eliminate spontaneous healing
ulcer to be included. Treatment with monochromatic phototherapy (Biolight® or placebo) will
be given locally, additional to standard care, three times weekly during the first four
weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed,
according to a pre-determined treatment plan. The area of the ulcer will be measured once
weekly for 20 weeks or until the ulcer is completely healed.
Description of Biolight® Therapy and device The therapy works by applying, for each
indication, a specific combination of pulsating monochromatic light to specific areas of the
body. The therapy is non-invasive, non-thermal, and based on the effects of pulsed
monochromatic light in the visible or near-visible spectrum.
The Biolight® Therapy - mechanism of action Light is a pre-requisite for most living
organisms, and human being have learnt to use light in many different situations, not least
in health care, where light is widely used in various therapeutic contexts every day. X-ray
is used as an investigational tool. In treating skin diseases, such as psoriasis, we use UV
radiation. Laser has been successful, both in surgery and for pain relief, and white light
treatment is recommended in seasonal depressions
Light is in fact electromagnetic radiation using various wavelengths. These wavelengths are
perceived as different colours. Red and violet light consist of long and shorter wavelength
respectively. Light consisting of all the wavelengths is perceived as white. There is an
electromagnetic field in light containing energy, which can be used in different treatment
situations.
In the healing process of wounded tissue basal components need access to energy and oxygen.
If the amount of energy is insufficient, the healing process is retarded. By the use of
monochromatic light, having a predetermined energy level and a specific wavelength, we can
contribute to the expected amount of energy demand. Applied at a chosen pulse frequency and
for a carefully calculated period of time, the wounded cells are provided with energy,
increasing their activity as well as the oxygen supply in the damaged area. That may promote
a faster healing.
The Biolight Therapy is suggested to shorten treatment time and reduce treatment costs and
to improve quality of life. This non-invasive treatment is thought to be complementary to
traditional therapies. The method is simple, painless and without known side effects.
The Biolight Care Device The Biolight® Care Device is a CE-marked medical device certified
in accordance with the Medical Device Directive (MDD; 93/42/EEC), with the size of the palm
of the hand.
The device contains 30 diodes emitting infrared light at 956 nm and also 80 diodes emitting
red light at 637 nm. Infrared and red pulsed monochromatic light are used in a unique
triple-stepped sequence. Infrared light, with an irradiance of ~55 W/m2, is combined with
red light, with an irradiance of ~21 W/m2. Using a duty cycle of 80%, both infrared and red
light are pulsed at the following frequencies during the first week: infrared/red 78 Hz,
infrared/red 702 Hz, infrared/red 8572,2Hz and from the second week: infrared/red 15,6 Hz,
infrared/red 287 Hz, infrared/red124 Hz. The choice of pulse frequencies and wavelengths are
based on earlier observations in both in-vitro and in-vivo studies. The equipment for both
monochromatic phototherapy and placebo (no irradiance output from the diodes) is identical
in appearance.
Previous studies - light therapy Treatment with pulsed electromagnetic fields for 40 minutes
improves micro vascular perfusion of the skin (1). In a literature overview from 1965 to
2003 on low-laser therapy for wound healing, focusing on both in vitro models and in vivo
animal and human studies, some studies reported increased cell proliferation and collagen
production; improvements in surgical wound healing were found in a rodent model; and, in
humans, beneficial effects on superficial wound healing found in small case series have not
been replicated in larger studies (2). In none of the reviewed studies was the exact
mechanism of photo thermal, photochemical or photomechanical action, reported.
The precise mode of action of low-laser therapy on wound healing is still unknown (2). In a
meta-analytic study of 34 peer-reviewed papers on the efficacy of low-power lasers in tissue
repair, a positive effect was shown on collagen formation, rate of healing, tensile
strength, and time needed for wound closure (3). In an experimental study on pressure ulcers
in mice, a significant positive effect was shown on wound healing after treatment with
low-laser therapy and this effect was independent of the temperature on the skin surface
(4). In a systematic review of the effects of low-level laser therapy on wound healing in
cell studies and animal model experiments by Lucas et al. (5), the 36 included studies
contained 49 outcome parameters, of which 30 reported the positive effect of laser
irradiation and 19 did not. The methodological quality of many studies was poor, and
in-depth analysis of the studies with the highest methodological quality scores showed no
significant pooled effect in favour of treatment (5).
A study of 20 spinal cord-injured patients with 22 pressure ulcers showed faster healing
with a combination of ultrasound/ultraviolet-C and laser treatment, compared with nursing
care alone (6). In a prospective, observer-blinded, multicenter randomized clinical study on
the efficacy of low-level laser therapy in 86 patients with stage III decubitus ulcers, no
evidence was found that justified the use of low-level laser therapy (7).
Previous studies - Biolight® A double-blind randomized placebo-controlled study on pressure
ulcer in elderly patients showed a statistically significant difference between patients
treated with monochromatic pulsating light (Biolight®) or placebo together with standard
care. This study was conducted on 163 patients as a multi-centre study at 9 centres in
Sweden and Denmark (8, 9). The mean normalised reduction in pressure ulcer size at week 12
was 0.79 for the phototherapy group and 0.50 for the placebo group (95 % CI 0.01-0.53;
p=0.039). No serious side effects were noted. The conclusion was that monochromatic
pulsating light fastened healing in grade II pressure ulcers in elderly patients.
A sub group analysis for the patient with diabetic foot ulcer in the above study showed a
strong tendency to improved healing (diff 71.3%).
A controlled, randomised, open study on the effect of Biolight® phototherapy in comparison
to conventional treatment in 74 patients with grade II or III chronic pressure ulcers was
conducted at Huddinge hospital (10). This study showed a statistically significant decreased
time to healing, in the phototherapy treated group compared with the control group.
A clinical study of 26 elderly patients with decubitus ulcers showed that monochromatic
phototherapy, Biolight®, had an effect on the microcirculation in the edge of the decubitus
ulcer with an increase of the oxygen supply to the tissue. (12).
Two in-vitro studies on the growth of skin fibroblast cells, using monochromatic
phototherapy showed that the two wavelengths and the low and high pulse frequencies used in
the Biolight® Wound Care program significantly influenced skin fibroblast cell growth
(personal communication Kratz & Huss Karolinska Institute, Stockholm, Sweden).
In an animal study (exposure 5 times a week during a 2-week period), with similar equipment
and similar infrared and red light exposure as in the present study, no adverse effect was
found (11).
Study population Diabetic patients with foot ulcers will be randomised to active
phototherapeutic treatment plus standard care treatment or placebo phototherapeutic
treatment plus standard care for diabetic foot ulcers.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02652754 -
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers
|
Phase 1 | |
Completed |
NCT01070433 -
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Completed |
NCT00971048 -
Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds
|
N/A | |
Terminated |
NCT00762138 -
The AutoloGel™ Post-Market Surveillance (TAPS) Program
|
N/A | |
Completed |
NCT00578604 -
Non-Invasive Assessment of Wound Healing With Optical Methods
|
N/A | |
Completed |
NCT05417425 -
Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers
|
Phase 1 | |
Completed |
NCT02631512 -
Evaluation of Woulgan in Diabetic Foot Ulcer
|
Phase 4 | |
Terminated |
NCT01816633 -
Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT02222376 -
Effect of Topic Pirfenidone in Diabetic Ulcers
|
Phase 3 | |
Completed |
NCT01454401 -
LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01221207 -
Instant Total Contact Cast to Heal Diabetic Foot Ulcers
|
N/A | |
Withdrawn |
NCT01105884 -
Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01291160 -
Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
|
Phase 2/Phase 3 | |
Completed |
NCT00536744 -
Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers
|
Phase 3 | |
Terminated |
NCT00316537 -
Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers
|
Phase 1/Phase 2 | |
Completed |
NCT00013299 -
Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3
|
Phase 2 | |
Completed |
NCT00013286 -
A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk
|
Phase 2 | |
Terminated |
NCT02667327 -
A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer
|
Phase 3 | |
Not yet recruiting |
NCT00916292 -
Safety Study of Topical Human FGF-1 for Wound Healing
|
Phase 1 | |
Completed |
NCT01154374 -
A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)
|
Phase 2 |